May 14, 2025
Rgenta Therapeutics Announces Presentation of Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, at the European Hematology Association (EHA) 2025 Congress
May 13, 2025
Rgenta Therapeutics Presents Data from Proprietary RSwitch Technology Demonstrating Versatile, Tunable Transgene Expression in AAV-Delivered Gene Therapies with Orally Administered Small Molecules (RDrugs)
Apr 30, 2025
Rgenta Therapeutics Announces Presentation of Preclinical Data from Proprietary RSwitch Technology at the American Society of Gene And Cell Therapy (ASGCT) 2025 Annual Meeting
Mar 25, 2025
Rgenta Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) 2025 Annual Meeting
Dec 09, 2024
Rgenta Therapeutics Presents Preclinical Data Demonstrating Anti-Tumor Activity of Oral Small Molecule MYB Inhibitor, RGT-61159, in Multiple Models of AML at the 66th American Society of Hematology (ASH) Annual Meeting
Dec 04, 2024
Rgenta Therapeutics Announces Strategic Alliance with GSK to Develop RNA-Targeted Small Molecule Splice Modulators
Nov 05, 2024
Rgenta Therapeutics Announces Presentation at the 66th American Society of Hematology (ASH) Annual Meeting
Oct 08, 2024
Rgenta Therapeutics Announces First Patients Dosed in Phase 1a/b Clinical Trial of RGT-61159, an Oral Small Molecule Targeting MYB, in Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC)
Jul 10, 2024
Rgenta Therapeutics Announces FDA Clearance of IND Application for RGT-61159, an Oral Small Molecule RNA Modulator Designed to Halt Disease-Driver MYB Production in Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC)
May 31, 2024
Rgenta Therapeutics Presents Preclinical Data from Lead Program RGT-61159, a Potent Inhibitor of Oncogenic MYB Synthesis, at the American Society of Clinical Oncology Annual Meeting (ASCO 2024)
Jan 30, 2024
Rgenta Therapeutics Joins The Leukemia & Lymphoma Society Therapy Acceleration Program®
Apr 02, 2020
Rgenta Therapeutics Launches with $20 Million Seed Investment